Human Genome Sciences ( HGSI) provided biotech's biggest summer shocker Monday with positive results from a phase III study of the lupus drug Benlysta.

The news drove Human Genome shares up 226.2% to $10.83 in recent trading. Shares of Benlysta partner GlaxoSmithKline ( GSK) were up 3.5% to $37.63.

Thoughts and observations stemming from the announcement:

Second Study

The big question for Human Genome is whether the success in the first phase III study of Benlysta predicts a win in the second phase III study, results of which will be announced in November. The positive BLISS-52 study enrolled patients primarily in Asia, South America and Eastern Europe. The study still under way, known as BLISS-76, is treating patients mainly from North America and Europe. Other than that, the studies are largely identical.

The placebo effect in the BLISS-52 was high (44% of placebo patients responded), so with treatments of lupus patients generally better in Western countries, will this hurt Benlysta's chances in BLISS-76?

Human Genome officials spent a good amount of time addressing this question on the company's conference call this morning. Simply put, the company is confident that BLISS-52's success bodes well for BLISS-76 results in November.

The evidence to back up that confidence is substantial. The results from BLISS-52 were very strong, so the drug has a lot of wiggle room just in case, for instance, placebo patients perform even better. Human Genome deserves a lot of credit for a well-designed study, including conceiving a novel primary endpoint that seems to have finally cracked lupus where previous studies failed.

If you liked this article you might like

Goodbye

Goodbye CytRx, Your Game Is Over

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio